FGFR Signaling Maintains a Drug Persistent Cell Population Following Epithelial-mesenchymal Transition

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Nov 9

PMID 27825137

Citations 36

Authors

Wells S Brown

Saeed Salehin Akhand

Michael K Wendt

Affiliations

Soon will be listed here.

Abstract

An emerging characteristic of drug resistance in cancer is the induction of epithelial-mesenchymal transition (EMT). However, the mechanisms of EMT-mediated drug resistance remain poorly defined. Therefore, we conducted long-term treatments of human epidermal growth factor receptor-2 (Her2)-transformed breast cancer cells with either the EGFR/Her2 kinase inhibitor, Lapatinib or TGF-β, a known physiological inducer of EMT. Both of these treatment regimes resulted in robust EMT phenotypes, but upon withdrawal a subpopulation of TGF-β induced cells readily underwent mesenchymal-epithelial transition, where as Lapatinib-induced cells failed to reestablish an epithelial population. The mesenchymal population that remained following TGF-β stimulation and withdrawal was quickly selected for during subsequent Lapatinib treatment, manifesting in inherent drug resistance. The Nanostring cancer progression gene panel revealed a dramatic upregulation of fibroblast growth factor receptor 1 (FGFR1) and its cognate ligand FGF2 in both acquired and inherent resistance. Mechanistically, FGF:Erk1/2 signaling functions to stabilize the EMT transcription factor Twist and thus maintain the mesenchymal and drug resistant phenotype. Finally, Lapatinib resistant cells could be readily eliminated using recently characterized covalent inhibitors of FGFR. Overall our data demonstrate that next-generation targeting of FGFR can be used in combination with Her2-targeted therapies to overcome resistance in this breast cancer subtype.

Citing Articles

Receptor tyrosine kinases in breast cancer treatment: unraveling the potential.

Qi Y, Deng S, Wang K Am J Cancer Res. 2024; 14(9):4172-4196.

PMID: 39417188 PMC: 11477839. DOI: 10.62347/KIVS3169.

Fibroblast growth receptor 1 is regulated by G-quadruplex in metastatic breast cancer.

Lin H, Safdar M, Washburn S, S Akhand S, Dickerhoff J, Ayers M Commun Biol. 2024; 7(1):963.

PMID: 39122837 PMC: 11316068. DOI: 10.1038/s42003-024-06602-x.

Starfysh integrates spatial transcriptomic and histologic data to reveal heterogeneous tumor-immune hubs.

He S, Jin Y, Nazaret A, Shi L, Chen X, Rampersaud S Nat Biotechnol. 2024; 43(2):223-235.

PMID: 38514799 PMC: 11415552. DOI: 10.1038/s41587-024-02173-8.

CRISPR/Cas9-mediated silencing of CD44: unveiling the role of hyaluronic acid-mediated interactions in cancer drug resistance.

Xu Z Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(5):2849-2876.

PMID: 37991544 DOI: 10.1007/s00210-023-02840-8.

The impact of poor metabolic health on aggressive breast cancer: adipose tissue and tumor metabolism.

Sankofi B, Valencia-Rincon E, Sekhri M, Ponton-Almodovar A, Bernard J, Wellberg E Front Endocrinol (Lausanne). 2023; 14:1217875.

PMID: 37800138 PMC: 10548218. DOI: 10.3389/fendo.2023.1217875.

References

Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-51. PMC: 3176718. DOI: 10.1038/onc.2010.215. View

Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M . Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. Biochem Biophys Res Commun. 2011; 407(1):219-24. DOI: 10.1016/j.bbrc.2011.03.002. View

Wendt M, Schiemann B, Parvani J, Lee Y, Kang Y, Schiemann W . TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer. Oncogene. 2012; 32(16):2005-15. PMC: 3721373. DOI: 10.1038/onc.2012.230. View

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

Azuma K, Kawahara A, Sonoda K, Nakashima K, Tashiro K, Watari K . FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor. Oncotarget. 2014; 5(15):5908-19. PMC: 4171601. DOI: 10.18632/oncotarget.1866. View

Kalluri R . EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 2009; 119(6):1417-9. PMC: 2689122. DOI: 10.1172/JCI39675. View

Taube J, Herschkowitz J, Komurov K, Zhou A, Gupta S, Yang J . Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A. 2010; 107(35):15449-54. PMC: 2932589. DOI: 10.1073/pnas.1004900107. View

Rexer B, Arteaga C . Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012; 17(1):1-16. PMC: 3394454. DOI: 10.1615/critrevoncog.v17.i1.20. View

Warzecha C, Jiang P, Amirikian K, Dittmar K, Lu H, Shen S . An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J. 2010; 29(19):3286-300. PMC: 2957203. DOI: 10.1038/emboj.2010.195. View

10.

Stuhlmiller T, Miller S, Zawistowski J, Nakamura K, Beltran A, Duncan J . Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. Cell Rep. 2015; 11(3):390-404. PMC: 4408261. DOI: 10.1016/j.celrep.2015.03.037. View

11.

Sun T, Fu J, Shen T, Lin X, Liao L, Feng X . The Small C-terminal Domain Phosphatase 1 Inhibits Cancer Cell Migration and Invasion by Dephosphorylating Ser(P)68-Twist1 to Accelerate Twist1 Protein Degradation. J Biol Chem. 2016; 291(22):11518-28. PMC: 4882423. DOI: 10.1074/jbc.M116.721795. View

12.

Tan L, Wang J, Tanizaki J, Huang Z, Aref A, Rusan M . Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci U S A. 2014; 111(45):E4869-77. PMC: 4234547. DOI: 10.1073/pnas.1403438111. View

13.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

14.

Sharpe R, Pearson A, Herrera-Abreu M, Johnson D, Mackay A, Welti J . FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2011; 17(16):5275-86. PMC: 3432447. DOI: 10.1158/1078-0432.CCR-10-2727. View

15.

Chaffer C, Marjanovic N, Lee T, Bell G, Kleer C, Reinhardt F . Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 2013; 154(1):61-74. PMC: 4015106. DOI: 10.1016/j.cell.2013.06.005. View

16.

Wendt M, Taylor M, Schiemann B, Sossey-Alaoui K, Schiemann W . Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers. Breast Cancer Res. 2014; 16(2):R24. PMC: 4053226. DOI: 10.1186/bcr3623. View

17.

Wendt M, Tian M, Schiemann W . Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression. Cell Tissue Res. 2011; 347(1):85-101. PMC: 3723118. DOI: 10.1007/s00441-011-1199-1. View

18.

Hong J, Zhou J, Fu J, He T, Qin J, Wang L . Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness. Cancer Res. 2011; 71(11):3980-90. PMC: 3107354. DOI: 10.1158/0008-5472.CAN-10-2914. View

19.

Brown W, Tan L, Smith A, Gray N, Wendt M . Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer. Mol Cancer Ther. 2016; 15(9):2096-106. PMC: 5010989. DOI: 10.1158/1535-7163.MCT-16-0136. View

20.

Brooks M, Burness M, Wicha M . Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. Cell Stem Cell. 2015; 17(3):260-71. PMC: 4560840. DOI: 10.1016/j.stem.2015.08.014. View